Jing Su

Title: Inventor Jing Su: Pioneering Innovations in Protein Modulation

Introduction

Jing Su, an accomplished inventor based in New York, NY, is recognized for her significant contribution to the field of biochemistry through her innovation in protein modulation. With a keen focus on developing pharmacologically useful inhibitors, Jing is making strides in therapeutic applications that can impact various health conditions.

Latest Patents

Jing boasts a notable patent titled "Modulators of Protein Tyrosine Phosphatases (PTPases)," which features novel compounds designed to inhibit protein tyrosine phosphatases such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR, and HePTP. This patent not only represents her innovative approach but also illustrates her dedication to advancing medical science by providing new avenues for treatment.

Career Highlights

Currently, Jing is a key member of Novo Nordisk A/S, where she applies her expertise in biochemistry and drug development. Her career is characterized by a commitment to research and innovation, reflecting her passion for creating an impact in the pharmaceutical industry.

Collaborations

Jing has collaborated with notable professionals in her field, including Lutz Stefan Richter and Henrik Sune Andersen. Working alongside talented colleagues enhances her research capabilities and fosters an environment of innovation, enabling the pursuit of groundbreaking solutions in protein modulation.

Conclusion

With her single, yet significant patent, Jing Su stands as a testament to the potential of innovation in the sciences. Through her work at Novo Nordisk A/S and collaboration with fellow researchers, she continues to push the boundaries of what is possible in the realm of protein modulation, paving the way for future advancements in healthcare and pharmaceuticals.